#USA #Hong Kong #Ascletis #Obesity Treatment #oral peptides

Ascletis Revolutionizes Obesity Treatment with Innovative Once-Weekly Oral Peptides

Ascletis Pharma Inc., a pioneering biotechnology firm, has made headlines with its groundbreaking announcement on the progress of its once-weekly oral peptide pipeline for obesity treatment. These developments have significant implications for metabolic diseases, showcasing Ascletis' dedication to advancing therapeutics in a clinically effective manner.

Comprehensive Pipeline

Ascletis' pipeline is notably comprehensive, featuring a first-in-class amylin receptor peptide agonist, identified as ASC36o, which is currently undergoing Phase I clinical trials in the United States. Early results reveal promising data, including a half-life of approximately 7 days and an oral bioavailability of between 6% to 8% in studies conducted with non-human primates (NHPs). These attributes suggest that ASC36o could be a viable once-weekly solution for those battling obesity.

Adding further weight to its offering, the company is also exploring two first-in-class combination therapies: the ASC36_37o FDC and ASC36_35o FDC, which blend amylin with various incretin agonists in a convenient oral tablet format. Such advancements position Ascletis uniquely within the competitive landscape of obesity treatments, as they represent a novel approach combining efficacy and patient convenience.

Examining the Clinical Data

The data reported from head-to-head comparisons with alternative therapies indicate that ASC36 outperformed both eloralintide and petrelintide in body weight reduction among rats with diet-induced obesity (DIO), achieving body weight reductions of 32% and 91% more effectively, respectively. This suggests that Ascletis' innovative compounds could provide significant benefits to patients and healthcare providers alike.

As the various combinations of peptides within the Ascletis pipeline continue to mature, the company anticipates their Investigational New Drug (IND) submissions will occur by the fourth quarter of 2026. This upcoming milestone will enable further exploration and potential expansion of treatment options for obesity and related metabolic conditions.

Advanced Technology Platform

At the heart of Ascletis' remarkable developments lies its proprietary Peptide Oral Transport Enhancement Technology (POTENT), which enhances the oral bioavailability of its peptide candidates through optimized gastric and intestinal absorption. The technology is designed to minimize variability in pharmacokinetics (PK), improving the overall therapeutic profiles of the compounds being developed.

With the foundation of POTENT, ASC36o and its associated FDCs exhibit increased absorption rates, leading to prolonged half-lives and improved bioavailability, which are crucial factors for effective weekly dosing regimens. As evidenced by ongoing research, the ASC36_37o FDC demonstrates a half-life extension from ASC36o's initial 7 days to around 8.3 days, showcasing the potential for improved treatment experiences for patients.

A Vision for the Future

As Ascletis continues to advance the development of its innovative oral peptide pipeline, Dr. Jinzi Jason Wu, Founder, Chairman, and CEO of Ascletis, highlighted the significance of these milestones. The integration of four validated targets—amylin, GLP-1, GIP, and GCG receptors—distinguishes Ascletis’ pipeline as a leader within the industry, reflecting its strategic commitment to addressing obesity on multiple fronts.

In summary, Ascletis Pharma’s dedication to pioneering therapies against obesity is marked by robust preclinical data and continuing research priorities. Their once-weekly oral peptide pipeline not only represents a novel class of obesity treatments but also redefines the way we approach metabolic health solutions. The expectation of further results in 2026 reinforces their leadership in the biotechnology landscape as they push toward a healthier future for those battling obesity.